• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Incyte Corp (NQ: INCY )

    75.87 -1.86 (-2.39%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Incyte Corp

    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Cracking The Code: Understanding Analyst Reviews For Incyte
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
    The major indexes declined, but haven't fallen apart. 
    Via Investor's Business Daily
    Incyte Breaks Out To 17-Month High As Jakafi Demand Surges
    Sales of the company's two key products, Jakafi and Opzelura, jumped. 
    Via Investor's Business Daily
    Peeling Back The Layers: Exploring Incyte Through Analyst Insights
    Via Benzinga
    Uncovering Noteworthy Technical Analysis Findings for INCYTE CORP (NASDAQ:INCY).
    NASDAQ:INCY may be ready to breakout. 
    Via Chartmill
    Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock
    Incyte reports strong Q3 earnings, driven by Jakafi growth, prompting BofA upgrade with a new price target of $90. 
    Via Benzinga
    Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
    Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
    Via Benzinga
    This Alphabet Analyst Turns Bullish; Here Are Top 5 Downgrades For Wednesday
    Via Benzinga
    Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura
    Incyte reports Q3 revenue of $1.04B, driven by strong Jakafi and Opzelura sales, and raises 2024 guidance amid competitive market challenges. 
    Via Benzinga
    Corning Posts Upbeat Q3 Earnings, Joins Opera, Inari Medical, Incyte And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    A Look Into Incyte Inc's Price Over Earnings
    Via Benzinga
    Assessing Incyte: Insights From 11 Financial Analysts
    Via Benzinga
    Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
    Aquestive Therapeutics hosted a virtual investor day, announcing advancements in Anaphylm and AQST-108. The company aims for FDA meetings in late 2024, targeting a 2025 NDA submission, while HC... 
    Via Benzinga
    Exposures Product Safety
    Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
    Truist Securities has downgraded Incyte due to concerns over Jakafi's patent expiration in 2028. Jakafi, Incyte's top-selling drug, faces potential revenue decline amid generic competition. Truist... 
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    Wall Street Lower Ahead Of Interest Rate Move
    Stocks are slightly lower this afternoon, as investors hope for the Federal Open Market Committee (FOMC) to issue its first interest rate cut in four years later today. 
    Via Talk Markets
    Intel Leads S&P 500 Monday, And Keeps Running Late; Apple Chipmakers Are Biggest Losers
    Intel kept running late on yet another big deal. 
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities
    Incyte Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
    Via Benzinga
    Analyst Expectations For Incyte's Future
    Via Benzinga
    Analyst Ratings For Incyte
    Via Benzinga
    Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study
    Incyte's Phase 3 inMIND trial of Monjuvi (tafasitamab) combined with lenalidomide and rituximab meets primary endpoints in relapsed follicular lymphoma patients, showing positive progression-free... 
    Via Benzinga
    Exposures Product Safety
    FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication
    The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at least two prior therapies, providing new hope for those with this serious... 
    Via Benzinga
    Exposures Product Safety
    After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial
    MacroGenics will discontinue vobra duo for remaining mCRPC participants after five deaths. New data to be presented at ESMO 2024 conference. 
    Via Benzinga
    Topics Death
    Exposures Death
    Incyte's Q2 Earnings: Wider Than Expected Loss, Pipeline Review, Lifts Jakafi Sales Guidance
    Incyte reported Q2 revenue of $1.04 billion, beating consensus, with Jakafi revenue at $705.9 million and Opzelura revenue up 52%. Despite an adjusted EPS loss, the company updated its 2024 Jakafi... 
    Via Benzinga
    Looking for growth without the hefty price tag? Consider NASDAQ:INCY.
    INCYTE CORP (NASDAQ:INCY) is showing decent growth, but is still valued reasonably. 
    Via Chartmill
    NASDAQ:INCY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
    INCYTE CORP (NASDAQ:INCY), an undervalued stock with good fundamentals. 
    Via Chartmill
    S&P 500 Hits Record Highs, Eyes 6th Straight Gain As Powell Keeps Bears At Bay; Tesla Targets 10th Consecutive Win, Bank Stocks Rally: What's Driving Markets Tuesday?
    The S&P 500 index climbed to new all-time highs, rising 0.3% during Tuesday’s session, aiming for a potential sixth consecutive positive close and remaining resilient after Fed Chair Jerome Powell‘s... 
    Via Benzinga
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    The 3 Most Undervalued Cathie Wood Stocks to Buy in July 2024
    The stock market watches this investing guru's picks closely but these may be the best undervalued Cathie Wood stocks in her ETFs. 
    Via InvestorPlace
    7 Cheap Biotech Stocks With Major Upside Potential
    While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks. 
    Via InvestorPlace
    3 Highly Rated Biotech Stocks for Your July Buy List
    Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street. 
    Via InvestorPlace
    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.